Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/10/20
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2020 Results - Quick Version Earnings Call TranscriptSeeking Alpha • 11/10/20
Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim DataBusiness Wire • 11/09/20
Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from SingaporeBusiness Wire • 11/09/20
Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020Business Wire • 10/30/20
Arcturus Therapeutics (ARCT) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/29/20
Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) DeficiencyBusiness Wire • 10/05/20
Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases ConferenceBusiness Wire • 10/01/20
Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine CandidateGlobeNewsWire • 09/04/20
Are Options Traders Betting on a Big Move in Arcturus Therapeutics (ARCT) Stock?Zacks Investment Research • 09/03/20
Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of HealthGlobeNewsWire • 08/18/20
Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 studyGlobeNewsWire • 08/11/20
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/11/20
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/10/20
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 08/10/20
Why Earnings Season Could Be Great for Arcturus Therapeutics (ARCT)?Zacks Investment Research • 08/07/20
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 07/31/20
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common StockGlobeNewsWire • 07/29/20